All articles
Long-form reporting on ibogaine research, organized by topic. New articles are reviewed by clinicians or researchers before publication.
Kentucky's bid to fund ibogaine research with opioid settlement money stalls
A 2023 proposal to direct $42 million in opioid settlement funds toward an ibogaine clinical trial was withdrawn after leadership changes at the commission overseeing the allocation.
Why noribogaine's long half-life complicates dosing protocols
Ibogaine's primary metabolite, noribogaine, persists in plasma for days after a single dose, raising questions about cumulative cardiac exposure that current monitoring protocols may not fully capture.
Inside the cardiac screening protocols used at the most rigorous clinics
A review of pre-treatment screening at clinics affiliated with academic research programs reveals consistent practices — and significant variation in how exclusion criteria are applied.
The Bwiti tradition and the long road from initiation rite to clinical compound
Iboga has been used ceremonially by the Bwiti of Gabon for at least two centuries. Western pharmacology's encounter with it began in the late nineteenth century — and reframed it in ways the originating tradition did not.
Neuroplasticity claims about ibogaine: what preclinical models actually show
Animal studies suggest ibogaine and noribogaine upregulate GDNF and BDNF expression. Translating those findings into claims about clinical efficacy requires distinctions that popular coverage often blurs.
What an FDA breakthrough therapy designation would and would not change
Advocates have called for the FDA to grant ibogaine breakthrough therapy status. The designation would accelerate review timelines but would not itself resolve the underlying evidentiary questions.